PFIZER INC Debt Securities, Available-for-sale and Held-to-maturity
PFIZER INC (PFE) had Debt Securities, Available-for-sale and Held-to-maturity of $9.14 billion as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Investments › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity · last filed 2026-08-04
- 2026-06-28: Debt Securities, Available-for-sale and Held-to-maturity $9.14B.
- 2026-03-29: Debt Securities, Available-for-sale and Held-to-maturity $9.55B.
- 2025-12-31: Debt Securities, Available-for-sale and Held-to-maturity $9.91B.
- 2025-09-28: Debt Securities, Available-for-sale and Held-to-maturity $11.54B.
| Period end | Debt Securities, Available-for-sale and Held-to-maturity |
|---|---|
| 2026-06-28 | $9.14B 10-Q · filed 2026-08-04 |
| 2026-03-29 | $9.55B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $9.91B 10-Q · filed 2026-08-04 |
| 2025-09-28 | $11.54B 10-Q · filed 2025-11-04 |
| 2025-06-29 | $10.36B 10-Q · filed 2025-08-05 |
| 2025-03-30 | $14.94B 10-Q · filed 2025-05-05 |
| 2024-12-31 | $11.81B 10-K · filed 2026-02-26 |
| 2024-09-29 | $7.73B 10-Q · filed 2024-11-04 |
| 2024-06-30 | $5.51B 10-Q · filed 2024-08-05 |
| 2024-03-31 | $9.16B 10-Q · filed 2024-05-08 |
| 2023-12-31 | $5.12B 10-K · filed 2025-02-27 |
| 2023-10-01 | $28.49B 10-Q · filed 2023-11-08 |
| 2023-07-02 | $25.42B 10-Q · filed 2023-08-09 |
| 2023-04-02 | $17.46B 10-Q · filed 2023-05-10 |
| 2022-12-31 | $21.81B 10-K · filed 2024-02-22 |
| 2022-10-02 | $24.03B 10-Q · filed 2022-11-09 |
| 2022-07-03 | $27.79B 10-Q · filed 2022-08-10 |
| 2022-04-03 | $19.73B 10-Q · filed 2022-05-11 |
| 2021-12-31 | $24.58B 10-K · filed 2023-02-23 |
| 2021-10-03 | $26.30B 10-Q · filed 2021-11-12 |
| 2021-07-04 | $17.71B 10-Q · filed 2021-08-12 |
| 2021-04-04 | $10.64B 10-Q · filed 2021-05-13 |
| 2020-12-31 | $10.12B 10-K · filed 2022-02-24 |
| 2020-09-27 | $8.37B 10-Q · filed 2020-11-05 |
| 2020-06-28 | $8.38B 10-Q · filed 2020-08-06 |
| 2020-03-29 | $4.75B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $8.34B 10-K · filed 2021-02-25 |
| 2019-09-29 | $5.92B 10-Q · filed 2019-11-07 |
| 2019-06-30 | $7.01B 10-Q · filed 2019-08-08 |
| 2019-03-31 | $8.79B 10-Q · filed 2019-05-09 |
| 2018-12-31 | $16.84B 10-K · filed 2020-02-27 |
| 2018-09-30 | $16.51B 10-Q · filed 2018-11-08 |
| 2018-07-01 | $14.43B 10-Q · filed 2018-08-09 |
| 2017-12-31 | $22.31B 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |